Promoting Research on Modeling and Simulation
Open Access
- 1 March 2025
- journal article
- review article
- Published by Pharmaceutical Society of Japan in YAKUGAKU ZASSHI
- Vol. 145 (3) , 223-246
Abstract
As I recently retired from Chiba University, I would like to describe how I began my research career, some of my accomplishments in the research field of modeling and simulation, and future prospects in this area. Here, I discuss the research topics of drug interactions, the oral absorption of drugs, analyses of between-group and individual differences in pharmacokinetics based on the theories of physiologically-based pharmacokinetics and population pharmacokinetics, and my roles in implementation of the drug interaction guideline. Furthermore, I also discuss modeling topics unrelated to pharmacokinetics, i.e., the analyses of the long-term progression of chronic diseases, such as Alzheimer's disease, Parkinson's disease, and chronic obstructive pulmonary disease using individual patient information; the spread of the coronavirus disease 2019 (COVID-19) pandemic; and prognostic factors of chronic heart failure with the view towards personalized medicine. After completing my Master's course at Hokkaido University, I joined a pharmaceutical company and worked as a pharmacokinetics researcher for 21 years, while obtaining my doctoral degree. I spent the next 9 years as a hospital pharmacist focusing on scientific research at the University of Tokyo Hospital, and the last 10 years as a Professor of Clinical Pharmacology and Pharmacometrics at Chiba University. My career is, therefore, characterized by involvement in pharmaceutical sciences from many different perspectives. This description focuses rather on the background of the studies than scientific details.Keywords
This publication has 45 references indexed in Scilit:
- Data‐driven disease progression model of Parkinson's disease and effect of sex and genetic variantsCPT: Pharmacometrics & Systems Pharmacology, 2024
- Model‐based meta‐analysis of ethnic differences and their variabilities in clearance of oral drugs classified by clearance mechanismCPT: Pharmacometrics & Systems Pharmacology, 2023
- Age-Related Change in Hepatic Clearance Inferred from Multiple Population Pharmacokinetic Studies: Comparison with Renal Clearance and Their Associations with Organ Weight and Blood FlowClinical Pharmacokinetics, 2021
- Model-based meta-analysis of changes in circulatory system physiology in patients with chronic heart failureCPT: Pharmacometrics & Systems Pharmacology, 2021
- A Novel Method to Estimate Long‐Term Chronological Changes From Fragmented Observations in Disease ProgressionClinical Pharmacology & Therapeutics, 2018
- Notable Drug–Drug Interaction Between Etizolam and Itraconazole in Poor Metabolizers of Cytochrome P450 2C19The Journal of Clinical Pharmacology, 2017
- Fear2014
- Bayesian estimation of pharmacokinetic parameters of vancomycin in patients with decreasing renal functionJournal of Pharmaceutical Sciences, 2012
- Prediction of Nonlinear Intestinal Absorption of CYP3A4 and P-Glycoprotein Substrates from their In Vitro Km ValuesPharmaceutical Research, 2011
- Efficacy and Safety of Exercise Training in Patients With Chronic Heart FailureJAMA, 2009